Table 2.
Patient, tumour and hospital characteristics of patients diagnosed with non‐metastatic muscle‐invasive bladder cancer between 1 November 2017 and 31 October 2019 included in the BlaZIB study, by treatment.
| Treatment | ||||
|---|---|---|---|---|
| Total | Untreated | Treated | P * | |
| Total, N (%) | 2116 (100.0) | 410 (19.4) | 1706 (80.6) | |
| Patient characteristics | ||||
| Gender, n (%) | 0.1895 | |||
| Male | 1506 (71.2) | 281 (68.5) | 1225 (71.8) | |
| Female | 610 (28.8) | 129 (31.5) | 481 (28.2) | |
|
Median age at diagnosis, years IQR |
74.0 67.0–81.0 |
83.0 77.0–87.0 |
72.0 65.0–78.0 |
<0.0001 |
| Age at diagnosis, n (%) | <0.0001 | |||
| <75 years | 1089 (51.5) | 73 (17.8) | 1016 (59.6) | |
| ≥75 years | 1027 (48.5) | 337 (82.2) | 690 (40.4) | |
|
Median BMI, kg/m 2 IQR (missing %) |
25.7 23.2–28.7 (8.3%) |
24.6 22.2–27.2 (17.8%) |
25.9 23.5–29.0 (6.0%) |
0.0002 |
| BMI, n (%) | <0.0001 | |||
| <18.5 kg/m2, underweight | 41 (1.9) | 10 (2.4) | 31 (1.8) | |
| 18.5–25 kg/m2, normal weight | 810 (38.3) | 174 (42.4) | 636 (37.3) | |
| 25–30 kg/m2, overweight | 775 (36.6) | 109 (26.6) | 666 (39.0) | |
| ≥30 kg/m2, obesity | 315 (14.9) | 44 (10.7) | 271 (15.9) | |
| Unknown | 175 (8.3) | 73 (17.8) | 102 (6.0) | |
| Weighted CCI score, n (%) | <0.0001 | |||
| 0 | 766 (36.2) | 89 (21.7) | 677 (39.7) | |
| 1 | 594 (28.1) | 120 (29.3) | 474 (27.8) | |
| 2 | 335 (15.8) | 84 (20.5) | 251 (14.7) | |
| 3 or more | 299 (14.1) | 94 (22.9) | 205 (12.0) | |
| Unknown | 122 (5.8) | 23 (5.6) | 99 (5.8) | |
| Type of comorbidity ** , n (%) | ||||
| Diabetes | 383 (31.2) | 99 (33.2) | 284 (30.5) | 0.3841 |
| Chronic pulmonary disease | 345 (28.1) | 82 (27.5) | 263 (28.3) | 0.7988 |
| Myocardial infarct | 197 (16.0) | 36 (12.1) | 161 (17.3) | 0.0322 |
| Peripheral vascular disease | 218 (17.8) | 57 (19.1) | 161 (17.3) | 0.4753 |
| Any tumour | 200 (16.3) | 55 (18.5) | 145 (15.6) | 0.2438 |
| Cerebrovascular disease | 237 (19.3) | 71 (23.8) | 166 (17.8) | 0.0229 |
| Moderate or severe renal disease | 208 (16.9) | 60 (20.1) | 148 (15.9) | 0.0910 |
| Congestive heart failure | 93 (7.6) | 35 (11.7) | 58 (6.2) | 0.0018 |
| Ulcer disease | 41 (3.3) | 11 (3.7) | 30 (3.2) | 0.6971 |
| Connective tissue disease | 55 (4.5) | 14 (4.7) | 41 (4.4) | 0.8335 |
| Dementia | 34 (2.8) | 22 (7.4) | 12 (1.3) | <0.0001 |
| Metastatic solid tumour (other than bladder cancer) | 24 (2.0) | 11 (3.7) | 13 (1.4) | 0.0128 |
| Mild liver disease | 19 (1.5) | 3 (1.0) | 16 (1.7) | 0.3850 |
| Diabetes with end‐organ damage | 27 (2.2) | 10 (3.4) | 17 (1.8) | 0.1176 |
| Hemiplegia or paraplegia | 11 (0.9) | 4 (1.3) | 7 (0.8) | 0.3472 |
| HIV | 3 (0.2) | ‐ | 3 (0.3) | 0.3263 |
| ECOG performance status, n (%) | <0.0001 | |||
| 0 | 654 (30.9) | 32 (7.8) | 622 (36.5) | |
| 1 | 438 (20.7) | 53 (12.9) | 385 (22.6) | |
| ≥2 | 231 (10.9) | 78 (19.0) | 153 (9.0) | |
| Unknown | 793 (37.5) | 247 (60.2) | 546 (32.0) | |
| Renal function: eGFR, mL/min/1.73m 2 (missing %) |
63.0 47.0–81.0 (25.1%) |
48.0 32.0–65.0 (18.3%) |
67.8 52.0–83.0 (26.7%) |
<0.0001 |
| SES, n (%) | 0.0087 | |||
| Low | 634 (30.0) | 147 (35.9) | 487 (28.5) | |
| Middle | 729 (34.5) | 128 (31.2) | 601 (35.2) | |
| High | 537 (25.4) | 91 (22.2) | 446 (26.1) | |
| Unknown | 216 (10.2) | 44 (10.7) | 172 (10.1) | |
| Previous surgery, n (%) | 0.0531 | |||
| Yes | 545 (25.8) | 108 (26.3) | 437 (25.6) | |
| No | 1514 (71.6) | 284 (69.3) | 1230 (72.1) | |
| Unknown | 57 (2.7) | 18 (4.4) | 39 (2.3) | |
| Previous radiation, n (%) | 0.0221 | |||
| Yes | 84 (4.0) | 26 (6.3) | 58 (3.4) | |
| No | 1979 (93.5) | 373 (91.0) | 1606 (94.1) | |
| Unknown | 53 (2.5) | 11 (2.7) | 42 (2.5) | |
| Tumour characteristics | ||||
| cT stage (TNM) , n (%) | 0.0286 | |||
| cT2 | 1477 (69.8) | 292 (71.2) | 1185 (69.5) | |
| cT3 | 506 (23.9) | 83 (20.2) | 423 (24.8) | |
| cT4a | 133 (6.3) | 35 (8.5) | 98 (5.7) | |
| Focality of the tumour, n (%) | 0.0016 | |||
| Multifocal | 508 (24.0) | 104 (25.4) | 404 (23.7) | |
| Unifocal | 1533 (72.4) | 280 (68.3) | 1253 (73.4) | |
| Unknown | 75 (3.5) | 26 (6.3) | 49 (2.9) | |
| Localization of the tumour, n (%) | 0.4045 | |||
| Trigone | 173 (8.2) | 39 (9.5) | 134 (7.9) | |
| Dome | 91 (4.3) | 12 (2.9) | 79 (4.6) | |
| Right or left wall | 566 (26.7) | 100 (24.4) | 466 (27.3) | |
| Anterior wall | 59 (2.8) | 12 (2.9) | 47 (2.8) | |
| Posterior wall | 109 (5.2) | 21 (5.1) | 88 (5.2) | |
| Bladder neck | 78 (3.7) | 14 (3.4) | 64 (3.8) | |
| Left or right ureteric orifice | 103 (4.9) | 22 (5.4) | 81 (4.7) | |
| Overlapping localisations | 724 (34.2) | 138 (33.7) | 586 (34.3) | |
| Unknown | 213 (10.1) | 52 (12.7) | 161 (9.4) | |
| Hospital characteristics | ||||
| Type of hospital, n (%) | 0.0019 | |||
| Community | 910 (43.0) | 190 (46.3) | 720 (42.2) | |
| Non‐university referral | 1115 (52.7) | 215 (52.4) | 900 (52.8) | |
| University | 91 (4.3) | 5 (1.2) | 86 (5.0) | |
| Discussed in MDTM, n (%) | <0.0001 | |||
| Yes, discussed in MDTM | 1963 (92.8) | 314 (76.6) | 1649 (96.7) | |
| No MDTM documented | 153 (7.2) | 96 (23.4) | 57 (3.3) | |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; eGFR: estimated glomerular filtration rate; IQR, interquartile range; MDTM, multidisciplinary team meeting; SES, socioeconomic status.
*
P value was calculated using Chi‐square for categorical variables and ANOVA for continuous variables.
**
Type of comorbidity was only considered for patients with a Charlson Comorbidity Index score of 1 or higher.